Abandoning the Proteinopathy Paradigm in Parkinson Disease

Proteins Do Not Replicate, They Precipitate: Phase Transition and Loss of Function Toxicity in Amyloid Pathologies

(2022) Kariem Ezzat et al.   Biology-Basel

Trial of Prasinezumab in Early-Stage Parkinson’s Disease

(2022) Gennaro Pagano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trial of Cinpanemab in Early Parkinson’s Disease

(2022) Anthony E. Lang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Low soluble amyloid-β 42 is associated with smaller brain volume in Parkinson's disease

(2021) Alberto J. Espay et al.   PARKINSONISM & RELATED DISORDERS

Unknown

(2018)   ANNALS OF NEUROLOGY

Is Alpha-Synuclein Loss-of-Function a Contributor to Parkinsonian Pathology? Evidence from Non-human Primates

(2016) Timothy J. Collier et al.   Frontiers in Neuroscience

Does α-synuclein have a dual and opposing effect in preclinical vs. clinical Parkinson's disease?

(2014) Katerina Markopoulou et al.   PARKINSONISM & RELATED DISORDERS

Differential levels of  -synuclein,  -amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease

(2010) K. Kasuga et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

In Vivo RNAi-Mediated α-Synuclein Silencing Induces Nigrostriatal Degeneration

(2010) Oleg S Gorbatyuk et al.   MOLECULAR THERAPY